About peripheral
T-cell lymphoma

Learn more about your cancer and see
how
ADCETRIS could help

Peripheral T-cell lymphomas are a type of non-Hodgkin lymphoma that develop from white blood cells called T cells. T cells are part of the body’s immune system. When working properly, the immune system helps your body fight off the infections and diseases, including cancer.

The importance of CD30

ADCETRIS is a CD30-directed treatment. This means that it works by targeting cells that have CD30, a protein that can be found on cancer cells, including peripheral T-cell lymphoma cells.

Even though CD30 is not usually found on healthy cells, ADCETRIS may affect them and cause side effects.

If your cancer cells have CD30, you may benefit from treatment with ADCETRIS.

Testing for CD30 protein

Depending on your T-cell lymphoma diagnosis, your doctor may order a test to find out how much CD30 is on your cancer cells. In some cases, the test result may be negative, meaning that your doctor may conclude that CD30 protein was not found. In reality, the amount of CD30 may just be very low.

Any amount of CD30, even as low as 1%, means that ADCETRIS could be a treatment option for you

If your doctor says that the CD30 test results are negative, ask them to check if there is any CD30 protein present on your cancer cells, no matter how low.

Model portrayal

Have you recently been
diagnosed with peripheral
T-cell lymphoma?

There are many types of peripheral T-cell lymphomas, each with different characteristics. Different types include:

  • Adult T-cell lymphoma/leukemia
  • Angioimmunoblastic T-cell lymphoma
  • Enteropathy-associated T-cell lymphoma
  • Peripheral T-cell lymphoma not otherwise specified
  • Cutaneous T-cell lymphomas
  • Systemic anaplastic large cell lymphoma

See how ADCETRIS plus chemotherapy worked in previously untreated adults with systemic anaplastic large cell lymphoma or other CD30-expressing T-cell lymphomas.

Relapsed primary cutaneous anaplastic large cell lymphoma and mycosis fungoides

Primary cutaneous anaplastic large cell lymphoma (pcALCL) and mycosis fungoides (MF) are 2 different types of cutaneous T-cell lymphoma, a type of blood cancer that involves the skin.

  • Mycosis fungoides is the most common type of cutaneous T-cell lymphoma, occurring in about 50% of cases
  • Primary cutaneous anaplastic large cell lymphoma happens less often

If your cancer has come back, there are still treatments that can help.

See how ADCETRIS worked in adults with relapsed primary cutaneous anaplastic large cell lymphoma or CD30-expressing mycosis fungoides.

Relapsed systemic anaplastic large cell lymphoma

Systemic anaplastic large cell lymphoma (sALCL) is a fast-growing type of T-cell lymphoma. It may appear in the skin, lymph nodes, bones, soft tissues, lungs, or liver. Its cancer cells have CD30 protein on them.

Anaplastic large cell lymphomas comprise about 1% of all non-Hodgkin lymphomas and about 10-20% of all T-cell lymphomas.

If your cancer comes back after combination chemotherapy, there are treatments that can help.

See how ADCETRIS worked in adults with relapsed systemic anaplastic large cell lymphoma.

Glossary

Relapse: When cancer has returned after a period of remission.

Remission: When signs and symptoms of cancer are reduced or undetectable.

Interested in starting ADCETRIS?

Important Safety Information

What is the most important information I should know about ADCETRIS?

  • PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML): Patients treated with ADCETRIS can have a rare, serious brain infection called PML that can lead to death. Tell your doctor immediately if you have mood or behavior changes, confusion, problems in thinking or loss of memory, changes in vision, speech, or walking, or decreased strength or weakness on one side of the body. PML may also be caused by prior treatments or diseases that weakened your immune system.
  • Do not take ADCETRIS if you are receiving bleomycin

What are the other possible serious side effects of ADCETRIS?

  • Nerve damage (peripheral neuropathy). Tell your doctor if you have any numbness or tingling in your hands or feet or any muscle weakness.
  • Allergic and infusion reactions. Tell your doctor if you experience symptoms of fever, chills, rash, or breathing problems within 24 hours of infusion. If you have a reaction, you may be given medicines before your ADCETRIS treatment.
  • Blood problems. Serious cases, including death, of fever with a low number of white blood cells have occurred with ADCETRIS. Serious cases of a low number of white blood cells, a low number of platelets, or a low number of red blood cells can occur.

    Your doctor will do blood tests to check your blood cell levels during ADCETRIS treatment. Your doctor may give you a medicine called G-CSF. Tell your doctor if you have a fever of 100.5°F or higher, chills, cough, or pain when you urinate.

  • Infections caused by bacteria, fungi, or viruses have been reported.
  • Tumor lysis syndrome is caused by the fast breakdown of cancer cells. Your doctor will monitor you for symptoms.
  • Patients with severe kidney disease or moderate or severe liver disease may have more side effects and deaths than patients without kidney or liver problems.
  • Liver problems. Serious liver problems, including death, can occur. Tell your doctor if you feel tired, do not feel like eating, have upper stomach pain, dark urine, or yellow skin and eyes (jaundice).
  • Lung problems. Serious lung problems, including death, can occur. Tell your doctor if you have a new cough, a cough that gets worse, or feel out of breath.
  • Skin problems called Stevens-Johnson syndrome and toxic epidermal necrolysis can happen. Tell your doctor if you have rash, hives, sores in your mouth, or blistering or peeling skin.
  • Gastrointestinal (GI) problems. Serious cases, including death, related to the pancreas, stomach, intestine, and colon can happen. If you have lymphoma that involves your stomach or intestine, you could have a higher risk of GI problems. Tell your doctor if you have severe stomach pain, chills, fever, nausea, vomiting, or diarrhea.
  • High blood sugar. Your doctor will test your blood during ADCETRIS treatment. Tell your doctor if you need to urinate more often than usual, are very thirsty, or have blurry vision.

The most common side effects in any study of ADCETRIS include:

  • nerve damage (peripheral neuropathy)
  • feeling tired
  • nausea
  • diarrhea
  • a low number of white blood cells
  • infection in the nose or sinuses
  • fever
  • constipation
  • vomiting
  • hair loss
  • weight loss
  • upper stomach pain
  • a low number of red blood cells
  • sores or swelling in the mouth and/or in the digestive tract
  • decrease in platelets
  • fever with a low number of white blood cells

These are not all the possible side effects of ADCETRIS. Tell your doctor about any side effect that bothers you or does not go away. If you have certain side effects, your doctor may lower your dose, delay, or stop your ADCETRIS treatment.

What should I tell my doctor before I start treatment with ADCETRIS?

  • All your medical conditions, including if you have kidney, liver, or lung problems, an infection, or diabetes.
  • If you are pregnant or plan to become pregnant. ADCETRIS may harm your unborn baby. Females who are able to become pregnant: Your doctor should give you a pregnancy test before starting ADCETRIS treatment. You should use effective birth control during ADCETRIS treatment and for 6 months after your last dose of ADCETRIS. Tell your doctor right away if you become pregnant or think you are pregnant during ADCETRIS treatment. Men with female partners who can get pregnant should use effective birth control during ADCETRIS treatment and for 6 months after the last dose.
  • If you are breastfeeding or plan to breastfeed. Do not breastfeed during ADCETRIS treatment.
  • All the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. ADCETRIS and certain other medicines can affect each other.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/Safety/MedWatch or call 1-800-FDA-1088.

Please see Important Facts about ADCETRIS, including IMPORTANT WARNING.

What is ADCETRIS?

ADCETRIS is a prescription medicine directed against the CD30 protein. It is used to treat:

  • Adults with previously untreated Stage 3 or 4 classical Hodgkin lymphoma, in combination with chemotherapy (Adriamycin, vinblastine, and dacarbazine)
  • Children 2 years of age and older with previously untreated high risk classical Hodgkin lymphoma, in combination with chemotherapy (doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide)
  • Adults with classical Hodgkin lymphoma at high risk of coming back or becoming worse after a stem cell transplant
  • Adults with classical Hodgkin lymphoma after a stem cell transplant fails or after at least 2 chemotherapy treatments fail and stem cell transplant is not an option
  • Adults with previously untreated systemic anaplastic large cell lymphoma or other CD30-expressing peripheral T-cell lymphomas, including angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphomas not otherwise specified, in combination with chemotherapy (cyclophosphamide, doxorubicin, and prednisone)
  • Adults with systemic anaplastic large cell lymphoma after at least 1 combination chemotherapy treatment fails
  • Adults with primary cutaneous anaplastic large cell lymphoma or CD30-expressing mycosis fungoides after systemic therapy (drugs that spread throughout the body)

Important Safety Information

What is the most important information I should know about ADCETRIS?

  • PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML): Patients treated with ADCETRIS can have a rare, serious brain infection called PML that can lead to death. Tell your doctor immediately if you have mood or behavior changes, confusion, problems in thinking or loss of memory, changes in vision, speech, or walking, or decreased strength or weakness on one side of the body. PML may also be caused by prior treatments or diseases that weakened your immune system.
  • Do not take ADCETRIS if you are receiving bleomycin

What are the other possible serious side effects of ADCETRIS?

  • Nerve damage (peripheral neuropathy). Tell your doctor if you have any numbness or tingling in your hands or feet or any muscle weakness.
  • Allergic and infusion reactions. Tell your doctor if you experience symptoms of fever, chills, rash, or breathing problems within 24 hours of infusion. If you have a reaction, you may be given medicines before your ADCETRIS treatment.
  • Blood problems. Serious cases, including death, of fever with a low number of white blood cells have occurred with ADCETRIS. Serious cases of a low number of white blood cells, a low number of platelets, or a low number of red blood cells can occur.

    Your doctor will do blood tests to check your blood cell levels during ADCETRIS treatment. Your doctor may give you a medicine called G-CSF. Tell your doctor if you have a fever of 100.5°F or higher, chills, cough, or pain when you urinate.

  • Infections caused by bacteria, fungi, or viruses have been reported.
  • Tumor lysis syndrome is caused by the fast breakdown of cancer cells. Your doctor will monitor you for symptoms.
  • Patients with severe kidney disease or moderate or severe liver disease may have more side effects and deaths than patients without kidney or liver problems.
  • Liver problems. Serious liver problems, including death, can occur. Tell your doctor if you feel tired, do not feel like eating, have upper stomach pain, dark urine, or yellow skin and eyes (jaundice).
  • Lung problems. Serious lung problems, including death, can occur. Tell your doctor if you have a new cough, a cough that gets worse, or feel out of breath.
  • Skin problems called Stevens-Johnson syndrome and toxic epidermal necrolysis can happen. Tell your doctor if you have rash, hives, sores in your mouth, or blistering or peeling skin.
  • Gastrointestinal (GI) problems. Serious cases, including death, related to the pancreas, stomach, intestine, and colon can happen. If you have lymphoma that involves your stomach or intestine, you could have a higher risk of GI problems. Tell your doctor if you have severe stomach pain, chills, fever, nausea, vomiting, or diarrhea.
  • High blood sugar. Your doctor will test your blood during ADCETRIS treatment. Tell your doctor if you need to urinate more often than usual, are very thirsty, or have blurry vision.

The most common side effects in any study of ADCETRIS include:

  • nerve damage (peripheral neuropathy)
  • feeling tired
  • nausea
  • diarrhea
  • a low number of white blood cells
  • infection in the nose or sinuses
  • fever
  • constipation
  • vomiting
  • hair loss
  • weight loss
  • upper stomach pain
  • a low number of red blood cells
  • sores or swelling in the mouth and/or in the digestive tract
  • decrease in platelets
  • fever with a low number of white blood cells

These are not all the possible side effects of ADCETRIS. Tell your doctor about any side effect that bothers you or does not go away. If you have certain side effects, your doctor may lower your dose, delay, or stop your ADCETRIS treatment.

What should I tell my doctor before I start treatment with ADCETRIS?

  • All your medical conditions, including if you have kidney, liver, or lung problems, an infection, or diabetes.
  • If you are pregnant or plan to become pregnant. ADCETRIS may harm your unborn baby. Females who are able to become pregnant: Your doctor should give you a pregnancy test before starting ADCETRIS treatment. You should use effective birth control during ADCETRIS treatment and for 6 months after your last dose of ADCETRIS. Tell your doctor right away if you become pregnant or think you are pregnant during ADCETRIS treatment. Men with female partners who can get pregnant should use effective birth control during ADCETRIS treatment and for 6 months after the last dose.
  • If you are breastfeeding or plan to breastfeed. Do not breastfeed during ADCETRIS treatment.
  • All the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. ADCETRIS and certain other medicines can affect each other.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/Safety/MedWatch or call 1-800-FDA-1088.

Please see Important Facts about ADCETRIS, including IMPORTANT WARNING.

What is ADCETRIS?

ADCETRIS is a prescription medicine directed against the CD30 protein. It is used to treat:

  • Adults with previously untreated Stage 3 or 4 classical Hodgkin lymphoma, in combination with chemotherapy (Adriamycin, vinblastine, and dacarbazine)
  • Children 2 years of age and older with previously untreated high risk classical Hodgkin lymphoma, in combination with chemotherapy (doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide)
  • Adults with classical Hodgkin lymphoma at high risk of coming back or becoming worse after a stem cell transplant
  • Adults with classical Hodgkin lymphoma after a stem cell transplant fails or after at least 2 chemotherapy treatments fail and stem cell transplant is not an option
  • Adults with previously untreated systemic anaplastic large cell lymphoma or other CD30-expressing peripheral T-cell lymphomas, including angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphomas not otherwise specified, in combination with chemotherapy (cyclophosphamide, doxorubicin, and prednisone)
  • Adults with systemic anaplastic large cell lymphoma after at least 1 combination chemotherapy treatment fails
  • Adults with primary cutaneous anaplastic large cell lymphoma or CD30-expressing mycosis fungoides after systemic therapy (drugs that spread throughout the body)

ADCETRIS and its logo, Seagen Secure and its logo, and Seagen and , are US registered trademarks of Seagen Inc. All other trademarks, trade names,
and service marks referred to herein are the property of their respective owners. Seagen is not associated with or sponsored by such trademark owners.

© 2022 Seagen Inc., Bothell, WA 98021

All rights reserved    US-BVP-22-113-MT